Biocon Biologics recognized as Asia IP Elite for 2025 by IAM

Published On 2025-12-17 06:30 GMT | Update On 2025-12-17 06:32 GMT

Bengaluru: Biocon Biologics, a fully integrated global biosimilars company and subsidiary of Biocon has announced that it has been recognized as an Asia IP Elite for 2025 by IAM (Intellectual Asset Management), the world’s leading Intellectual Property (IP) publication.

This prestigious accolade is awarded to a select group of Asia-based organizations that have demonstrated exceptional IP value creation and are considered leaders in the region. The award was presented during IPBC Asia, held in Tokyo from November 18–20, 2025.

Biocon first earned its place on the Asia IP Elite list in 2016. In subsequent years, Biocon Biologics has continued this legacy, with the two entities together being among the few Indian pharmaceutical companies consistently featured on the Asia IP Elite roster. The 2025 recognition marks the ninth consecutive year that Biocon and Biocon Biologics have appeared on this prestigious list.

Shreehas Tambe, CEO & Managing Director, Biocon Biologics, said, “Our inclusion in the Asia IP Elite list for 2025 marks the ninth consecutive year that Biocon and Biocon Biologics have appeared on this prestigious list. This reflects our sustained commitment to innovation and strong intellectual property strategy. It reinforces our growing stature as a global biosimilars leader and the role of our IP strategy in expanding access to high-quality, affordable therapies for patients worldwide.”

Each year, the IAM editorial team conducts an extensive research process, incorporating both quantitative and qualitative analyses, to highlight an exclusive group of leading corporations and research institutions as inductees into the Asia IP Elite.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Biocon Biologics recognized as Asia IP Elite for 2025 by IAM

Similar News

Lupin receives positive EMA comittee opinion for eye therapy Ranluspec

GSK twice yearly Exdensur secures USFDA approval for severe asthma

Lupin Nagpur injectable facility gets EIR from USFDA

Sun Pharma Asked to Resubmit Revised Phase III Protocol for Delafloxacin CABP Trial

Panacea Biotec appoints Vinod Goel as CFO

Class 8 Dropouts Used YouTube Tutorials to Make Fake Betnovate-C, Clop-G Creams, Delhi Police Bust 6-Year Racket

Bhagirath Place under scanner: 204 samples of syrups, medicines and surgical items lifted for testing